Spain's Personal Saving Percentage Rate
Rewritten Article:
Fresenius Steams Ahead with Spain and Cost-Cutting Drive in 2021
This year, Fresenius, a healthcare titan, is off to a flying start. The Q1 revenue and profits surged—Spain, particularly, dazzled with exceptional earnings and profitability. The projected targets are confirmed... and they're not holding back when it comes to tackling US trade policies, armed with solid arguments like the drug shortage issue.
Michael Sen, the CEO, is optimistic about hitting his annual goals despite potential US tariffs. Confident in their local manufacturing for the US market, they're geared to counter steep tariffs with robust arguments.
Pharmaceutical shortages have been reported in certain US regions. Sen clarified their efforts to engage in discussions demonstrating that domestic production can significantly alleviate the drug shortage predicament. The US segment comprises roughly around ten percent of their total revenue.
Sen underscored Fresenius's strong start to the year. Adjusted operating profit (EBIT) climbed by a robust 4% to €654 million, significantly outpacing analysts' projections. Cost reductions also contributed to the positive trajectory. Revenue jumped by a staggering 7% to €5.6 billion, also marking a 7% currency-neutral increase. Net income went up by a substantial 12% to €416 million.
Fresenius Helios, Europe's largest healthcare provider, flaunted "outstanding profitability" in Spain, balancing out losses in Germany post-expiry of energy cost subsidies. With an impressive 8% revenue boost to approximately €3.4 billion, EBIT at Fresenius Helios dipped by a modest 4% to €333 million. This figure includes a steep 23% drop in EBIT in Germany to €157 million.
Fresenius Kabi, the pharmaceutical segment offering drugs and products like artificial nutrition, experienced a 5% revenue increase to €2.14 billion, accompanied by a significant 16% increase in EBIT to €360 million.
By 2025, Fresenius aims to sustain a steady organic revenue growth rate of 4-6%. Expectations see adjusted operating profit hiking by 3-7% on a currency-neutral basis.
Sources: ntv.de, jwu/rts
- DAX Company
- Quarterly Results
- Fresenius
- Healthcare Industry
- Fresenius's Business Structure: Fresenius focuses on three core business segments:
- Fresenius Kabi: A key player in pharmaceuticals and medical devices.
- Fresenius Helios: A dominant figure in hospital operations and healthcare services.
- Fresenius Medical Care (FMC): Specializes in dialysis services.
- Despite facing potential US tariffs, Fresenius's CEO, Michael Sen, remains optimistic about meeting their annual goals, citing their robust employment policy of local manufacturing for the US market to counter steep tariffs.
- In the healthcare industry, Fresenius Kabi, a significant part of Fresenius's business structure, concentrates on pharmaceuticals and medical devices, including artificial nutrition products, and experienced a 5% revenue increase in Q1 2021.
- Fresenius Helios, another core business segment, operates in hospital operations and healthcare services, and foreign trade policies, particularly in Spain, have been instrumental in driving overall revenue growth, such as the 8% boost in Q1 2021, despite a 4% dip in EBIT.
- With an annual goal of sustaining a steady organic revenue growth rate of 4-6%, Fresenius is also forecasting a 3-7% increase in adjusted operating profit on a currency-neutral basis by 2025, as part of their community policy for business growth and success.
- Amidst the reported pharmaceutical shortages in certain US regions, Fresenius is actively engaging in discussions to demonstrate how their employment policy prioritizing domestic production could help alleviate the drug shortage predicament and foster improved health-and-wellness standards.
